#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The monoclonal antibody daratumumab in the treatment of multiple myeloma


Authors: M. Štork;  L. Pour;  V. Sandecká;  M. Krejčí;  Z. Adam;  Z. Král
Authors‘ workplace: Interní hematologická a onkologická klinika, FN Brno
Published in: Transfuze Hematol. dnes,22, 2016, No. 4, p. 230-237.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

The monoclonal antibody daratumumab is a new and effective drug for the treatment of multiple myeloma. Results of clinical trials have demonstrated a high efficacy in monotherapy and an even higher when used in combination. Daratumumab monotherapy in heavily-pre-treated patients showed a 30% overall response rate with response persisting for more than six months. Combination of daratumumab and immunomodulatory drugs has shown a more than 90% response rate and significant extension of progression-free survival versus standard care in relapsed patients. This review summarizes current preclinical and clinical data on daratumumab treatment in multiple myeloma.

Key words:
multiple myeloma – daratumumab – CD38 – monoclonal antibody


Sources

1. Kumar S, Rajkumar S, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. San-Miguel JF, Mateos MV. Can multiple myeloma become a curable disease? Haematologica 2011; 96: 1246–1248.

3. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015; 126(3): 300–310.

4. Cabanillas F. Rituximab in DLBCL: 6 years on. Lancet Oncol 2011; 12: 984–985.

5. Casak SJ, Lemery SJ, Shen YL, et al. U.S. Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukaemia. Oncologist 2011; 16: 97–104.

6. Nelson AL, Dhimolea E, Reichert JM, et al. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9(10): 767–774.

7. Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res 2011; 2011: 924058.

8. Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120(3): 552–559.

9. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621–631.

10. Zocchi E, Franco L, Guida L, et al. A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes. Biochem Biophys Res Commun 1993; 196: 1459–1465.

11. Deaglio S, Mehta K, Malavasi F, et al. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res 2001; 25: 1–12.

12. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol 1998; 160: 395–402.

13. Aarhus R, Graeff RM, Dickey DM, et al. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem 1995; 270: 30327–30333.

14. Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482–488.

15. Damle R, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

16. van de Donk NW, Janmaat ML, Mutis T, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 2016; 270(1): 95–112.

17. de Weers M, Tai YT, van der Veers MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.

18. Diebolder CA, Beurskens FJ, de Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014; 343: 1260–1263.

19. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2011; 96: 284-290.

20. Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 2015; 29: 2039–2049.

21. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 2015; 7: 311–321.

22. Preyat N, Leo O. Complex role of nicotinamide adenine dinucleotide in the regulation of programmed cell death pathways. Biochem Pharmacol 2016; 101: 13–26.

23. Jansen JH, Boross P, Overdijk MB, et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. American Society of Hematology Proceedings 2012. Blood 2012; 120(21): 2974.

24. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 2015; 373: 1207–1219.

25. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 2016; 387: 1151–1160.

26. Palumbo A, Chanan-Khan A, Wiesel K, et al. Phase 3 randomised controlled study of daratumumab, bortezomib a dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: CASTOR. Haematologica 2016; 101(S1): Abstract LB 2236.

27. Dimopulos M. Daratumumab shows remarkable benefit in relapsed or refractory multiple myeloma in the POLLUX Study. Haematologica 2016; 101(S1): Abstract LB 2238.

28. Mateos MV, Cavo M, Jakubowiak AJ, et al. A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone). J Clin Oncol 2015; 33(15 Suppl): Abstract TPS8608.

29. Janssen Research & Development LLC. Study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and dexamethasone in participants with previously untreated multiple myeloma (Nahlíženo 20. 7. 2016). Dostupné na https://clinicaltrials.gov/show/NCT02252172.

30. Intergroupe Francophone du Myelome. A study to evaluate daratumumab in transplant eligible participants with previously untreated multiple myeloma (Cassiopeia) (Nahlíženo 20.7.2016) Dostupné na https://clinicaltrials.gov/show/NTC02541383.

31. Mohandas N, Narla A. Blood group antigens in health and disease. Curr Opin Hematol 2005; 12: 135–140.

32. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion 2015; 55(6Pt 2): 1545-1554.

33. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: 538–548.

34. McCudden C, Axel A, Slaets D, et al. Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody. J Clin Oncol 2015; 33(15 Suppl): 8590.

35. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014; 123: 1826–1832.

36. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120(14): 2817–2825.

37. Cavo M, Pantani L, Pettruci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 9–19.

38. Gay F, Larocca A, Vijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025–3031.

39. Hájek R, Masszi T, Petrucci MT, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 2016 Elektronická verze zveřejněna 15.7.2016; doi: 10.1038/leu.2016.176.

40. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17(1): 27–38.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#